{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:57:43Z","timestamp":1792735063680,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105704","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T20:59:44Z","timestamp":1717793984000},"page":"105704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 \u2013 Results from a German cladribine cohort"],"prefix":"10.1016","volume":"88","author":[{"given":"Markus C.","family":"Kowarik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Woitschach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Cepek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicta","family":"K\u00fchnler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke","family":"Schlemilch-Paschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Grothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"J\u00f6stingmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105704_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104286","article-title":"Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study","volume":"71","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105704_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2024.105704_bib0003","series-title":"8th Congress of the European Academy of Neurology","article-title":"Treatment patterns prior to and post cladribine in patients with multiple sclerosis","author":"Ellenberger","year":"2022"},{"key":"10.1016\/j.msard.2024.105704_bib0004","series-title":"9th Joint ECTRIMS-ACTRIMS Meeting","article-title":"Clinical outcome in people with multiple sclerosis who switched from cladribine to ocrelizumab","author":"Ellenberger","year":"2023"},{"issue":"6","key":"10.1016\/j.msard.2024.105704_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: an ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2024.105704_bib0007","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.105704_bib0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","article-title":"Treatment with Cladribine Tablets Beyond Year 4: a Position Statement by Southeast European Multiple Sclerosis Centers","volume":"12","author":"Habek","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2024.105704_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104009","article-title":"Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: a prospective multicenter study","volume":"65","author":"Krajnc","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105704_bib0011","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","article-title":"Expert-Agreed Practical Recommendations on the Use of Cladribine","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol. Ther."},{"issue":"13","key":"10.1016\/j.msard.2024.105704_bib0012","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert. Opin. PharmacOther"},{"key":"10.1016\/j.msard.2024.105704_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2024.105704_bib0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"issue":"21","key":"10.1016\/j.msard.2024.105704_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215207","article-title":"Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study","volume":"10","author":"Rejdak","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.msard.2024.105704_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/cells12091243","article-title":"Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine","volume":"12","author":"Rolfes","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.msard.2024.105704_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1133967","article-title":"Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients","volume":"14","author":"Ruschil","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2024.105704_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","author":"S\u00f8rensen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824002815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:20:37Z","timestamp":1723605637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824002815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":16,"alternative-id":["S2211034824002815"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105704","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 \u2013 Results from a German cladribine cohort","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105704"}}